PCSK9 Proprotein convertase subtilisin/kexin type 9

Cat.No.	Name	Information
M3835	Alirocumab	Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia.
M24997	Tafolecimab	Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
M24947	Ongericimab	Ongericimab (JS002) is a humanized anti-PCSK9 IgG4ҡ monoclonal antibody for hypercholesterolemia and hyperlipidemia.
M24769	Frovocimab	Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
M24651	Ralpancizumab	Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.
M24650	Bococizumab	Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
M11345	Inclisiran	Inclisiran (ALN-PCSsc) is a first-in-class double-stranded small interfering RNA (siRNA) molecule and a PCSK9 inhibitor that inhibits the transcription of PCSK-9. Inclisiran is used in hyperlipidemia and cardiovascular disease (CVD) research.